医药健康是未来投资的_老虎社区_美港股上老虎

2021-06-06

医药健康是未来投资的取向！

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":112767229,"tweetId":"112767229","gmtCreate":1622935046861,"gmtModify":1622935046861,"author":{"id":3584704550443897,"idStr":"3584704550443897","authorId":3584704550443897,"authorIdStr":"3584704550443897","name":"王世全","avatar":"https://static.tigerbbs.com/dd2f3855063b94b8bb4000ff81f4a114","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>医药健康是未来投资的取向！</p></body></html>","htmlText":"<html><head></head><body><p>医药健康是未来投资的取向！</p></body></html>","text":"医药健康是未来投资的取向！","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/112767229","repostId":2140408437,"repostType":4,"repost":{"id":"2140408437","kind":"news","pubTimestamp":1622800499,"share":"https://www.laohu8.com/m/news/2140408437?lang=&edition=full","pubTime":"2021-06-04 17:54","market":"us","language":"zh","title":"《新股消息》科济药业(02171.HK)下周一起招股 引入礼来等9名基投","url":"https://stock-news.laohu8.com/highlight/detail?id=2140408437","media":"AAFN","summary":"内地生物制药公司科济药业公布招股详细，计划发行9,474.7万股，当中10%为本地发售，90%为国际配售，每股招股价介乎29.6至32.8元，集资最多约31.07亿元。每手500股入场费约16,565.26元，联席保荐人为高盛及瑞银。招股期由下周一起至下周四结束，料於6月18日上市。是次招股共引入9名基石投资者，包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金，合共认购约17.85亿元或2.3亿美元等值股份，设6个月禁售期。","content":"<html><body><p>内地生物制药公司科济药业(02171.HK)公布招股详细，计划发行9,474.7万股，当中10%为本地发售，90%为国际配售，每股招股价介乎29.6至32.8元，集资最多约31.07亿元。每手500股入场费约16,565.26元，联席保荐人为<a href=\"https://laohu8.com/S/GS\">高盛</a>及<a href=\"https://laohu8.com/S/UBS\">瑞银</a>。招股期由下周一(7日)起至下周四(10日)结束，料於6月18日上市。是次招股共引入9名基石投资者，包括<a href=\"https://laohu8.com/S/LLY\">礼来</a>亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、<a href=\"https://laohu8.com/S/000776\">广发证券</a>、Dymon Asia、常春藤及南方基金，合共认购约17.85亿元或2.3亿美元等值股份，设6个月禁售期。财务高级副总裁谢岚表示，由於公司尚未有产品商业化，因此过往几年录得经营亏损，去年度亏损达10.64亿元人民币，料於明年上半年就核心产品CT053提交中国新药上市申请。问到与热门新股<a href=\"https://laohu8.com/S/06699\">时代天使</a>(06699.HK)撞期，董事会主席、首席执行官兼首席科学官李宗海称，每家公司都有特点，投资者亦有不同关注重点，又指在研产品於临床实验中显示出有疗效及安全性，相信会得到市场认可。(gc/a)~阿思达克财经新闻网址: www.aastocks.com\t\t\t\t\t\t\t\t\t </p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》科济药业(02171.HK)下周一起招股 引入礼来等9名基投</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》科济药业(02171.HK)下周一起招股 引入礼来等9名基投\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 17:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1103479&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>内地生物制药公司科济药业(02171.HK)公布招股详细，计划发行9,474.7万股，当中10%为本地发售，90%为国际配售，每股招股价介乎29.6至32.8元，集资最多约31.07亿元。每手500股入场费约16,565.26元，联席保荐人为高盛及瑞银。招股期由下周一(7日)起至下周四(10日)结束，料於6月18日上市。是次招股共引入9名基石投资者，包括礼来亚洲基金、新华人寿、CloudAlpha...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1103479&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825","relate_stocks":{"02171":"科济药业-B"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1103479&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140408437","content_text":"内地生物制药公司科济药业(02171.HK)公布招股详细，计划发行9,474.7万股，当中10%为本地发售，90%为国际配售，每股招股价介乎29.6至32.8元，集资最多约31.07亿元。每手500股入场费约16,565.26元，联席保荐人为高盛及瑞银。招股期由下周一(7日)起至下周四(10日)结束，料於6月18日上市。是次招股共引入9名基石投资者，包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金，合共认购约17.85亿元或2.3亿美元等值股份，设6个月禁售期。财务高级副总裁谢岚表示，由於公司尚未有产品商业化，因此过往几年录得经营亏损，去年度亏损达10.64亿元人民币，料於明年上半年就核心产品CT053提交中国新药上市申请。问到与热门新股时代天使(06699.HK)撞期，董事会主席、首席执行官兼首席科学官李宗海称，每家公司都有特点，投资者亦有不同关注重点，又指在研产品於临床实验中显示出有疗效及安全性，相信会得到市场认可。(gc/a)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1240,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/112767229"}